Methods and compositions for transgene expression in a herpesvirus vector system
AssigneesUniversity of Miami, President and Fellows of Harvard College
InventorsRonald Desrosiers, Young Shin
Life of this patent
Estimating the term…
Abstract
Compositions are provided comprising a replication-competent herpesvirus vector system and/or a herpesvirus vector particle comprising a heterologous recombinant transgene of interest encoding an antigen of interest (e.g., a tumor-associated antigen, a microbial antigen, etc.), wherein the recombinant transgene has been modified to comprise a codon usage signature of a herpesvirus late gene operably linked to an active promoter. Such compositions find use in a variety of methods including, for example, methods of generating an immune response against an antigen of interest in a subject in need thereof, as well as methods for treating or preventing cancer or a microbial infection.
Claims58
A replication-competent herpesvirus vector system comprising a polynucleotide comprising a heterologous recombinant transgene of interest operably linked to a promoter, wherein said recombinant transgene of interest has been modified to comprise a codon usage signature of at least one herpesvirus late gene and wherein the at least one herpesvirus late gene corresponds to the herpesvirus vector system.
A replication-competent herpesvirus vector particle comprising within its genome a polynucleotide comprising a heterologous recombinant transgene of interest operably linked to a promoter, wherein said recombinant transgene has been modified to comprise a codon usage signature of at least one herpesvirus late gene, wherein the at least one herpesvirus late gene corresponds to the herpesvirus vector.
A method for treating or preventing a microbial infection in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a replication-competent herpesvirus vector particle comprising within its genome a polynucleotide comprising a heterologous recombinant transgene encoding a microbial antigen and operably linked to a promoter, wherein said recombinant transgene has been modified to comprise a codon usage signature of at least one herpesvirus late gene, wherein the at least one herpesvirus late gene corresponds to the herpesvirus vector, and wherein an immune response against said microbial antigen is generated in said subject and thereby treats or prevents said microbial infection.
A method for treating or preventing cancer in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a replication-competent herpesvirus vector particle comprising within its genome a polynucleotide comprising a heterologous recombinant transgene encoding a tumor-associated antigen and operably linked to a promoter, wherein said recombinant transgene has been modified to comprise a codon usage signature of at least one herpesvirus late gene, wherein the at least one herpesvirus late gene corresponds to the herpesvirus vector, and wherein an immune response against said tumor-associated antigen is generated in said subject and thereby treats or prevents said cancer.
Dependencies are inferred from the claim text.